CURRENT PUBLICATIONS

LABORATORY RESEARCH

The Canonical NF-kB Pathway is Required for Formation of Luminal Mammary Neoplasias and is Activated in the Mammary Progenitor Population
Data suggest that the canonical NF-kB pathway is active in normal luminal progenitor cells before transformation and is required for the formation of mammary luminal-type epithelial neoplasias. [Oncogene]

Reciprocal Effects of STAT5 and STAT3 in Breast Cancer
STAT5 can modify the effects of STAT3 from the level of gene expression to cellular phenotype and analysis of the activation state of both STAT5 and STAT3 may provide important diagnostic and prognostic information in breast cancer. [Mol Cancer Res]

Proteinase-Activated Receptor 2 Expression in Breast Cancer and its Role in Breast Cancer Cell Migration
Proteinase-activated receptor 2 (PAR2) agonists facilitate breast cancer cell chemokinesis through the Gi-c-Src-JNK-paxillin signaling pathway. [Oncogene]

The Par3/aPKC Interaction is Essential for End Bud Remodeling and Progenitor Differentiation During Mammary Gland Morphogenesis
Results reveal a new function for Par3 in the regulation of progenitor differentiation and epithelial morphogenesis in vivo and demonstrate for the first time an essential requirement for the Par3-aPKC interaction. [Genes & Dev]

Effects of Raf Kinase Inhibitor Protein Expression on Metastasis and Progression of Human Breast Cancer
Results indicate that Raf kinase inhibitor protein (RKIP) is a metastasis suppressor gene of human breast cancer. [Mol Cancer Res]

Breast Cancer Migration and Invasion Depend on Proteasome Degradation of Regulator of G-Protein Signaling 4
Preventing degradation of RGS4 protein should attenuate aberrant signal inputs from multiple Gi-coupled receptors, thereby retarding the spread of breast cancer cells and making them targets for surgery, radiation, and immune treatment. [Cancer Res]

GOLPH3 Modulates mTOR Signaling and Rapamycin Sensitivity in Cancer
Genomic and genetic, biological, functional and biochemical data in yeast and humans establishes GOLPH3 as a new oncogene that is commonly targeted for amplification in human cancer. [Nature]

Expression of FOXA1 and GATA-3 in Breast Cancer: The Prognostic Significance in Hormone Receptor-Negative Tumors
FOXA1 was a significant predictor of good outcome in breast cancer, whereas GATA-3 was an important luminal marker. The expression of FOXA1 may be used for risk stratification among ER-alpha-negative patients. [Breast Cancer Res]

A Functional Connection Between pRB and TGF-Beta in Growth Inhibition and Mammary Gland Development
Active transcriptional repression of E2F target genes by pRB downstream of CDKs is a key component of TGF-Beta cytostatic signaling. Results suggest a unique functional connection between pRB and TGF-Beta in growth control and mammary development. [Mol Cell Bio]

The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer
The humoral immune system plays a pivotal role in metastasis-free survival of carcinomas of the breast. [Cancer Res]

CLINICAL RESEARCH

Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers
Findings suggest that breast cancer stem cells identified as ALDH1-positive, but not CD44+/CD24-, play a significant role in resistance to chemotherapy. [Clin Cancer Res]

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. [N Engl J Med]

Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
There was no evidence for reduced benefit of trastuzumab in HER2 IHC2+FISH+ cases. The degree of HER2 amplification does not influence prognosis or benefit from adjuvant trastuzumab in patients treated with prior adjuvant chemotherapy. [J Clin Oncol]

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic therapies and biomarkers. [Clin Pharmacol Ther]

POLICY NEWS

Obama Uses Podium to Push Health-Care Reform
During a press conference held at the White House this afternoon, President Obama called on Americans to support health-care reform, among other policy initiatives.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!